Metabolic Longevity · 5mg × 10 vials
In plain terms: 5-Amino-1MQ is a research compound - oral, fast-acting and well studied.
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule selective inhibitor of NNMT (nicotinamide N-methyltransferase). It is not a peptide - it is a quinolinium-class oral compound that sits in the metabolic-longevity bucket because of overlapping use cases. NNMT does two things that work against fat loss: (1) it methylates nicotinamide (a NAD+ precursor) into 1-methylnicotinamide (1-MNA) for excretion, draining the NAD+ pool that mitochondria need to burn fuel, and (2) it consumes S-adenosylmethionine (SAM), which is the body's universal methyl donor for hundreds of epigenetic reactions. Obese adipose tissue expresses NNMT at much higher levels than lean tissue, which is part of what keeps fat cells locked in a storage phenotype.
When 5-Amino-1MQ blocks NNMT, nicotinamide gets recycled into NAD+ instead of excreted, intracellular NAD+ climbs, SAM is preserved, and the adipocyte's epigenetic program shifts from storage toward oxidation. Downstream effects include increased polyamine flux, higher energy expenditure, and stabilized Sirt1 (since the NNMT product 1-MNA normally suppresses Sirt1). In the foundational Neelakantan et al. 2019 work, diet-induced obese mice on 5-Amino-1MQ lost fat mass and adipocyte size dropped ~30% with no change in food intake. That last point matters: the mechanism is a passive metabolic shift, not appetite suppression. The body burns more without the user eating less. Human RCT data does not yet exist; the case for the compound rests on consistent preclinical results plus several years of community use that lines up with the predicted mechanism.
Typical dose ranges by experience level - educational reference. Message us and we tailor it to you.
Beginners feel energy/mood lift within days. Fat loss adjunct effect emerges at 2-4 weeks. The 50mg starting dose is what most clinics (BHRC, longevity practices) use as their default capsule strength. No need to inject - oral is the only practical route given the rat PK and human community data.
This is the modal dose across community reports and is what most stack guides default to. Split dosing (50mg AM + 50mg early PM) gives steadier plasma levels given the ~6-7hr oral half-life. Single morning dose is fine for most and is simpler.
Advanced users running 150mg are typically stacking with a GLP-1 for a plateau-break or running a recomp protocol with CJC+Ipa. Above 150mg the dose-response curve flattens in community reports - no clear benefit to 200mg+ over 150mg.
Straight talk - what people actually report, and what the studies measured.
Peer-reviewed studies and clinical guidelines - tap any to read the source.
foundational small-molecule study, ~30% adipocyte size reduction, no appetite effect
Read study ↗PubMedKraus et al, Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity, Nature 2014genetic-knockdown precursor study establishing NNMT as a metabolic target
Read study ↗PubMedRoberti et al, Roles of Nicotinamide N-Methyltransferase in Obesity and Type 2 Diabetes, PMC8337113, 2021review covering NAD+/SAM dynamics, Sirt1 axis, polyamine flux, and 5-Amino-1MQ in vivo data
Read study ↗PubMedBhujbal et al, LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: pharmacokinetic and oral bioavailability studies, 2021rat PK: oral t½ ~6.9 hr, IV t½ ~3.8 hr, oral bioavailability ~38%
Read study ↗PubMedNeelakantan et al follow-up, NNMT inhibition improves muscle function in aged mice, Scientific Reports 2019grip strength, endurance, and recovery improvements with NNMT inhibition
Read study ↗Physician commentaryBeverly Hills Rejuvenation Center 5-Amino-1MQ patient framing50mg capsule format, 4-8 week timeline framing for patient outcomes
Read study ↗Aggregated sentiment from public forums & socials - real-world reports, not individual endorsements.
Energy lift / mild stimulant feel: most common subjective effect, reported within 1-3 days of starting, persists through use
Mood/mental clarity uptick: commonly reported, attributed to elevated NAD+ and stabilized Sirt1 signaling
Insomnia if dosed late: clear signal in community reports - anyone dosing after ~2pm risks sleep disruption. Easy fix by AM-only dosing.
Mild GI upset (nausea, loose stools): uncommon, usually resolves by week 2 or with dosing alongside food
Headache: occasional, mostly week 1
Fat loss adjunct effect (1-3 lb over 4-8 weeks at 100mg/day standalone, more when stacked with GLP-1): the realistic standalone effect size is modest - this is a metabolic adjunct, not a primary weight-loss agent
Route: oral (capsule or reconstituted powder taken sublingually/orally)
Injection site: N/A - oral
Storage: reconstituted powder stored refrigerated, stable ~30 days. Unreconstituted vials room-temp stable but refrigerator is fine.
Notes: Take in the morning. Compound has mild stimulant-like energy effect for many users so AM dosing avoids insomnia. With or without food is fine - food can soften the rare GI upset. If splitting (e.g., 100mg AM + 50mg early afternoon), don't dose past 2pm. Oral bioavailability ~38% per rat PK studies, which is why the 50-150mg/day oral range is much higher than what was used in mouse subQ trials (20mg/kg).